[1]杜岑,都健.铁死亡调控机制与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2020,40(05):340-343.[doi:10.3760/cma.j.cn121383-20191227-12074]
　Du Cen,Du Jian.The mechanism of ferroptosis regulation and non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2020,40(05):340-343.[doi:10.3760/cma.j.cn121383-20191227-12074]
点击复制

铁死亡调控机制与非酒精性脂肪性肝病()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年05期
页码:
340-343
栏目:
综述
出版日期:
2020-09-20

文章信息/Info

Title:
The mechanism of ferroptosis regulation and non-alcoholic fatty liver disease
作者:
杜岑; 都健
中国医科大学附属第四医院第一内分泌代谢内科 110000
Author(s):
Du Cen;  Du Jian
Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of China Medical University, Shenyang 110000, China
关键词:
铁死亡;  非酒精性脂肪性肝病;  脂质过氧化;  铁代谢
Keywords:
Ferroptosis;  Non-alcoholic fatty liver disease;  Lipid peroxidation;  Iron metabolism
DOI:
10.3760/cma.j.cn121383-20191227-12074
文献标志码:
A
摘要:
细胞死亡是维持生命平衡的重要机制,广泛存在于人体各种生理病理过程中,并在多种疾病的发生、发展中起重要作用。近年来发现了一种新的细胞死亡方式—— 铁死亡,以铁代谢和活性氧簇代谢为调控机制,通过诱发活性氧簇堆积,直接或间接影响非酒精性脂肪性肝病的发病。目前非酒精性脂肪性肝病的发病机制尚不明确,且无有效 的治疗方法,通过对铁死亡的不断了解,阐明铁死亡对非酒精性脂肪性肝病的影响,可为其预防和治疗提供理论支持。
Abstract:
Cell death widely exists in various physiological and pathological processes of human body and plays a significant role in the occurrence and development of various diseases which is an important mechanism to maintain the balance of life. In recent years, ferroptosis,a new type of cell death mode has been found with iron metabolism and reactive oxygen metabolism as its regulation mechanisms. This type of cell death mode directly or indirectly affects the incidence of non-alcoholic fatty liver disease by inducing the accumulation of reactive oxygen species. At present, the pathogenesis of non-alcoholic fatty liver disease is not clear, and there are no effective treatment methods. With the continuous understanding of ferroptosis, the influence of ferroptosis on non-alcoholic fatty liver disease will be clarified, providing theoretical support for its prevention and treatment.

参考文献/References:

[1] Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J].Cell, 2014,156(1-2):317- 331.DOI:10.1016/j.cell.2013.12.010.
[2] Latunde-Dada GO. Ferroptosis:role of lipid peroxidation, iron and ferritinophagy[J].Biochim Biophys Acta Gen Subj, 2017,1861(8):1893- 1900.DOI:10.1016/j.bbagen.2017.05.019.
[3] 姜懿纳, 阳松威, 张欣, 等. 铁死亡的机制及其在神经疾病中的作用[J].中国药理学通报,2018,34(2):166-170.DOI:10.3969/j.issn.1001-1978.2018.02.005.
[4] Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis:a regulated cell death nexus linking metabolism, redox biology, and disease [J].Cell, 2017,171(2):273-285.DOI:10.1016/j.cell.2017.09.021.
[5] Masarone M, Rosato V, Dallio M, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease[J].Oxid Med Cell Longev, 2018,2018:9547613.DOI:10.1155/2018/9547613.
[6] 李余佳, 王玲, 金春, 等. 铁死亡的调控机制及其在肝疾病中的作用研究进展[J].中国药理学与毒理学杂志,2019,33(4):307-313.DOI:10.3867/j.issn.1000- 3002.2019.04.010.
[7] Yang Z, Wu J, Li X, et al. Association between dietary iron intake and the prevalence of nonalcoholic fatty liver disease:a cross-sectional study[J].Medicine(Baltimore), 2019,98(43):e17613.DOI:10.1097/MD.0000000000017613.
[8] Pan X, Chen B, Liu W, et al. Circulating iron levels interaction with central obesity on the risk of nonalcoholic fatty liver disease:a case- control study in southeast China[J].Ann Nutr Metab, 2019,74(3):207-214. DOI:10.1159/000497228.
[9] Rostoker G, Loridon C, Griuncelli M, et al. Liver iron load influences hepatic fat fraction in end-stage renal disease patients on dialysis:a proof of concept study[J].EBioMedicine,2019,39:461-471.DOI:10.1016/j.ebiom.2018.11.020.
[10] Kitade H, Chen G, Ni Y, et al. Nonalcoholic fatty liver disease and insulin resistance:new insights and potential new treatments[J].Nutrients, 2017,9(4):387.DOI:10.3390/nu9040387.
[11] Ma W, Feng Y, Jia L,et al. Dietary iron modulates glucose and lipid homeostasis in diabetic mice[J].Biol Trace Elem Res,2019,189(1):194- 200.DOI:10.1007/s12011-018-1446-3.
[12] Backe MB, Moen IW, Ellervik C, et al. Iron regulation of pancreatic beta-cell functions and oxidative stress[J].Annu Rev Nutr, 2016,36:241- 273.DOI:10.1146/annurev-nutr-071715-050939.
[13] Okada-Iwabu M, Iwabu M, Yamauchi T, et al. Drug development research for novel adiponectin receptor-targeted antidiabetic drugs contributing to healthy longevity[J].Diabetol Int,2019,10(4):237-244.DOI:10.1007/s13340-019-00409-6.
[14] Magni P, Macchi C, Sirtori CR, et al. Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases[J].Clin Chem Lab Med,2016,54(10):1579-1587. DOI:10.1515/cclm-2015-0953.
[15] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J].Cell Mol Life Sci,2019,76 (1):99-128. DOI:10.1007/s00018-018-2947-0.
[16] Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis[J].Cell Death Dis, 2019,10(6):449.DOI:10.1038/s41419-019-1678-y.
[17] Sui M, Jiang X, Chen J, et al. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway[J].Biomed Pharmacother,2018,106:125-133.DOI:10.1016/j.biopha.2018.06.060.
[18] Birerdinc A, Younossi ZM. Epigenome-wide association studies provide insight into the pathogenesis of non-alcoholic fatty liver disease and non- alcoholic steatohepatitis[J].Ann Hepatol, 2018,17(1):11-13.DOI:10.5604/01.3001.0010.7530.
[19] Yuan H, Li X, Zhang X, et al. Identification of ACSL4 as a biomarker and contributor of ferroptosis[J].Biochem Biophys Res Commun,2016,478 (3):1338-1343. DOI:10.1016/j.bbrc.2016.08.124.
[20] Stepanova M, Hossain N, Afendy A, et al. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease[J].Obes Surg, 2010,20(5):640-650.DOI:10.1007/s11695-010-0078-2.
[21] Zhang RN, Pan Q, Zheng RD, et al. Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease[J].Int J Mol Med,2018,42(1):443-452.DOI:10.3892/ijmm.2018.3583.
[22] Di Maggio R, Maggio A. The new era of chelation treatments:effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major[J].Br J Haematol,2017,178(5):676-688.DOI:10.1111/bjh.14712.
[23] Yan HF, Liu ZY, Guan ZA, et al. Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice[J].Endocr Connect, 2018,7(4):604-616.DOI:10.1530/EC-18-0054.
[24] Rodrigues de Morais T, Gambero A. Iron chelators in obesity therapy-old drugs from a new perspective?[J].Eur J Pharmacol, 2019,861:172614.DOI:10.1016/j.ejphar.2019.172614.
[25] Ma X, Pham VT, Mori H, et al. Iron elevation and adipose tissue remodeling in the epididymal depot of a mouse model of polygenic obesity[J].PLoS One, 2017,12(6):e0179889.DOI:10.1371/journal.pone.0179889.

相似文献/References:

[1]曹涵,曲伸.过氧化物酶体增殖物活化受体与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
　Cao Han,Qu Shen..Peroxisome proliferator-activated receptors and non-alcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2014,(05):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
[2]胡雅琴,包玉倩.维生素D对非酒精性脂肪性肝病的保护作用[J].国际内分泌代谢杂志,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
　Hu Yaqin,Bao Yuqian..Protective effect of vitamin D on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(05):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
[3]聂秀玲,李明珍,孙丽荣.高尿酸血症与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2016,36(02):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
　Nie Xiuling,Li Mingzhen,Sun Lirong..Hyperuricemia and non-alcoholic fatty liver[J].International Journal of Endocrinology and Metabolism,2016,36(05):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
[4]张洁,邸阜生.运动防治非酒精性脂肪性肝病的机制[J].国际内分泌代谢杂志,2016,36(06):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
　Zhang Jie,Di Fusheng..Mechanism of exercise on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2016,36(05):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
[5]张雅楠,郗光霞,杨翠萍,等.自噬在非酒精性脂肪性肝病中的变化及作用[J].国际内分泌代谢杂志,2017,37(01):11.[doi:10.3760/cma.j.issn.1673-4157.2017.01.03]
　Zhang Yanan*,Xi Guangxia,Yang Cuiping,et al.The change and function of autophagy in nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2017,37(05):11.[doi:10.3760/cma.j.issn.1673-4157.2017.01.03]
[6]李博,苏青.晚期糖基化终末产物及其受体与非酒精性脂肪性肝病的 关系[J].国际内分泌代谢杂志,2017,37(03):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
　Li Bo,Su Qing..Relationship between advanced glycation end-products and its receptor in nonalcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2017,37(05):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
[7]狄红杰,刘超.饮食干预对非酒精性脂肪性肝病肠道菌群的影响[J].国际内分泌代谢杂志,2017,37(04):254.
　Di Hongjie,Liu Chao..Effects of diet interventions on gut microbiota of nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2017,37(05):254.
[8]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
　Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(05):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[9]李霞 雷涛.铁过载与代谢性疾病的关系[J].国际内分泌代谢杂志,2018,38(01):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
　Li Xia*,Lei Tao..Relationship between iron overload and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(05):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
[10]曹白鸽 董艳.母体妊娠期高脂饮食所致的炎性反应状态对子代的影响[J].国际内分泌代谢杂志,2018,38(02):96.[doi:10.3760/cma.j.issn.1673-4157.2018.02.006]
　Cao Baige*,Dong Yan..Effects of inflammatory state on offspring induced by maternal high-fat diet during pregnancy[J].International Journal of Endocrinology and Metabolism,2018,38(05):96.[doi:10.3760/cma.j.issn.1673-4157.2018.02.006]

备注/Memo

备注/Memo:
基金项目:辽宁省教育厅项目(LQNK201715); 辽宁省科技厅项目(20170520272) 通信作者:都健,Email:dujian.com@medmail.com.cn
更新日期/Last Update: 2020-09-20